Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients

被引：11

作者：

Suttorp, Meinolf ^{[1
]}

Metzler, Markus ^{[2
]}

Millot, Frederic ^{[3
]}

Shimada, Hiroyuki ^{[4
]}

Bansal, Deepak ^{[5
]}

Gunes, Adalet Meral ^{[6
]}

Kalwak, Krzysztof ^{[7
]}

Sedlacek, Petr ^{[8
]}

Baruchel, Andre ^{[9
,10
]}

Biondi, Andrea ^{[11
]}

Hijiya, Nobuko ^{[12
]}

Schultz, Kirk R. ^{[13
]}

Schrappe, Martin ^{[14
]}

机构：

[1] Tech Univ, Univ Hosp Carl Gustav Carus, Div Pediat Hematol & Oncol, Fetscherstr 74, D-01307 Dresden, Germany

[2] Univ Erlangen Nurnberg, Univ Hosp, Dept Pediat Hematol & Oncol, Erlangen, Germany

[3] Univ Hosp, Pediat Oncol Unit, Poitiers, France

[4] Keio Univ, Dept Pediat, Sch Med, Tokyo, Japan

[5] Postgrad Inst Med Educ & Res, Dept Pediat Hematol Oncol, Chandigarh, India

[6] Uludag Univ Hosp, Dept Pediat Hematol, Gorukle, Turkey

[7] Med Univ, Dept Pediat Bone Marrow Transplantat Oncol & Hema, Wroclaw, Poland

[8] Charles Univ Motol, Med Sch 2, Teaching Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic

[9] Univ Hosp Robert Debre, AP HP, Pediat Hematol Immunol Dept, Paris, France

[10] Paris Diderot Univ, Pediat Hematol Immunol Dept, Paris, France

[11] Univ Milano Bicocca, Tettamanti Res Ctr, Dept Pediat, Monza, Italy

[12] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Hematol Oncol & Stem Cell Transplant, Chicago, IL 60611 USA

[13] BC Childrens Hosp, CIHR Wyeth Clin Res Chair Transplantat, Dept Pediat Oncol Res, Vancouver, BC, Canada

[14] Univ Klinikum Schleswig Holstein, Dept Gen Pediat, Univ Kinderklin, Campus Kiel, Kiel, Germany

来源：

PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 12期

关键词：

generic medication; imatinib inhibitor; pediatric; Ph plus leukemia; tyrosine kinase; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; FOLLOW-UP; MESYLATE; EFFICACY; CHILDREN; THERAPY; GLIVEC; SAFETY; TABLET;

D O I：

10.1002/pbc.27431

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome-positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

引用

页数：5

共 27 条

[1] Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back [J].

Alwan, Alaa Fadhil ;

Matti, Bassam F. ;

Naji, Aladdin S. ;

Muhammed, Abdulsalam H. ;

Abdulsahib, Manal A. .

LEUKEMIA & LYMPHOMA, 2014, 55 (12) :2830-2834

[2] Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy [J].

Atici, Esen Bellur ;

Karliga, Bekir .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2015, 114 :330-340

[3] Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice [J].

Awidi, Abdalla ;

Abbasi, Salah ;

Alrabi, Kamal ;

Kheirallah, Khalid A. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12) :E55-E61

[4] Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study [J].

Biondi, Andrea ;

Schrappe, Martin ;

De Lorenzo, Paola ;

Castor, Anders ;

Lucchini, Giovanna ;

Gandemer, Virginie ;

Pieters, Rob ;

Stary, Jan ;

Escherich, Gabriele ;

Campbell, Myriam ;

Li, Chi-Kong ;

Vora, Ajay ;

Arico, Maurizio ;

Roettgers, Silja ;

Saha, Vaskar ;

Valsecchi, Maria Grazia .

LANCET ONCOLOGY, 2012, 13 (09) :936-945

[5] Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest [J].

Danthala, Madhav ;

Gundeti, Sadashivudu ;

Kuruva, Siva Prasad ;

Puligundla, Krishna Chaitanya ;

Adusumilli, Praveen ;

Karnam, Ashok Pillai ;

Bala, Stalin ;

Konatam, Meher Lakshmi ;

Maddali, Lakshmi Srinivas ;

Digumarti, Raghunadha Rao .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07) :457-462

[6] Clinical efficacy of generic imatinib [J].

de Lemos, Mario L. ;

Kyritsis, Victoria .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (01) :76-79

[7] Outcome of Frontline Treatment with "Generic" Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study [J].

Entasoltan, B. ;

Bekadja, M. A. ;

Touhami, H. ;

Mehalhal, N. ;

Zouaoui, Z. ;

Mesli, N. ;

Talbi, M. ;

Bachiri, A. ;

Michallet, M. .

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2017, 9

[8] Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec [J].

Eskazan, Ahmet Emre ;

Sadri, Sevil ;

Keskin, Dilek ;

Ayer, Mesut ;

Kantarcioglu, Bulent ;

Demirel, Naciye ;

Aydin, Demet ;

Aydinli, Fuat ;

Yokus, Osman ;

Ozunal, Isil Erdogan ;

Berk, Selin ;

Yalniz, Fevzi Firat ;

Elverdi, Tugrul ;

Salihoglu, Ayse ;

Ar, Muhlis Cem ;

Ongoren, Seniz ;

Baslar, Zafer ;

Aydin, Yildiz ;

Tuzuner, Nukhet ;

Ozbek, Ugur ;

Soysal, Teoman .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12) :804-811

[9] Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer [J].

Geissler, J. ;

Sharf, G. ;

Cugurovic, J. ;

Padua, R. ;

Narbutas, S. ;

Remic, M. ;

Venkatesh, V. .

LEUKEMIA, 2016, 30 (12) :2396-2397

[10] Conformational polymorphism on imatinib mesylate: Grinding effects [J].

Grillo, Damian ;

Polla, Griselda ;

Vega, Daniel .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (02) :541-551

← 1 2 3 →